New Findings in World Health Organization Described by C. Anyakora and Co-Researchers (Cost benefit of investment on quality in pharmaceutical…

New Findings in World Health Organization Described by C. Anyakora and Co-Researchers (Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer)

By a News Reporter-Staff News Editor at Pharma Business Week -- Investigators discuss new findings in World Health Organization. According to news reporting out of Rockville, Maryland, by NewsRx editors, research stated, "Pharmaceutical companies in Africa need to invest in both facilities and quality management systems to achieve good manufacturing practice (GMP) compliance. Compliance to international GMP standards is important to the attainment of World Health Organization (WHO) prequalification."

Our news journalists obtained a quote from the research, "However, most of the local pharmaceutical manufacturing companies may be deterred from investing in quality because of many reasons, ranging from financial constraints to technical capacity. This paper primarily evaluates benefits against the cost of investing in GMP, using a Nigerian pharmaceutical company, Chi Pharmaceuticals Limited, as a case study. This paper also discusses how to drive more local manufacturers to invest in quality to attain GMP compliance; and proffers practical recommendations for local manufacturers who would want to invest in quality to meet ethical and regulatory obligations. The cost benefit of improving the quality of Chi Pharmaceuticals Limited's facilities and system to attain WHO GMP certification for the production of zinc sulfate 20-mg dispersible tablets was calculated by dividing the annual benefits derived from quality improvement interventions by the annual costs of implementing quality improvement interventions, referred to as a benefit-cost ratio (BCR). Cost benefit of obtaining WHO GMP certification for the production of zinc sulfate 20-mg dispersible tablets was 5.3 (95% confidence interval of 5.0-5.5). Investment in quality improvement intervention is cost-beneficial for local manufacturing companies. Governments and regulators in African countries should support pharmaceutical companies striving to invest in quality. Collaboration of local manufacturing companies with global companies will further improve quality."

According to the news editors, the research concluded: "Local pharmaceutical companies should be encouraged to key into development opportunities available for pharmaceutical companies in Africa."

For more information on this research see: Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer. BMC Health Services Research, 2017;17():12-20. BMC Health Services Research can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Health Services Research - www.biomedcentral.com/bmchealthservres/)

Our news journalists report that additional information may be obtained by contacting C. Anyakora, US Pharmacopeial Convent Inc, Promoting Qual Med Program, Rockville, MD 20852, United States. Additional authors for this research include O. Ekwunife, F. Alozie, M. Esuga, J. Ukwuru, S. Onya and J. Nwokike (see also World Health Organization).

Keywords for this news article include: Rockville, Maryland, United States, North and Central America, Government Agencies Offices and Entities, World Health Organization, Zinc Sulfate, Chemicals.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC